Literature DB >> 15804949

2-Arachidonoylglycerol increases in ischemia-reperfusion injury of the rat liver.

Makoto Kurabayashi1, Izumi Takeyoshi, Daisuke Yoshinari, Koshi Matsumoto, Ikuro Maruyama, Yasuo Morishita.   

Abstract

Several studies have implicated endocannabinoids in various forms of shock. However, the role of endocannabinoids in hepatic ischemia-reperfusion injury remains unclear. The purpose of this study was to evaluate the changes of two endocannabinoidsin hepatic ischemia-reperfusion injury: anandamide (ANA) and 2-arachidonoylglycerol (2-AG). Male Sprague-Dawley rats were divided into 2 groups: the short (15 min) ischemic group and the long (60 min)ischemic group in the segmental (70%) hepatic tissue. Blood levels of aspartate transaminase (AST), alanine transaminase (ALT), lactate dehydrogenase (LDH), ANA, and 2-AG were examined. Serum lev-els of AST, ALT, and LDH were significantly higher in the long-ischemia group than in the short-ischemia group. Plasma levels of 2-AG showed similar augmentation prior to and after reperfusion in both the short- and long-ischemia groups, although plasma 2-AG lev-els tended to be higher in the long-ischemia group than in the short-ischemia group. Plasma levels of ANA were augmented in the early phase of reperfusion in the short-ischemia group and did not differ significantly from the normal level with time after reperfusion in the long-ischemia group. These results suggest that the endocannabinoid 2-AG increases in hepatic ischemia-reperfusion injury of rats, rather than ANA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15804949     DOI: 10.1080/08941930590905189

Source DB:  PubMed          Journal:  J Invest Surg        ISSN: 0894-1939            Impact factor:   2.533


  14 in total

Review 1.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 2.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

3.  Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.

Authors:  Mohanraj Rajesh; Hao Pan; Partha Mukhopadhyay; Sándor Bátkai; Douglas Osei-Hyiaman; György Haskó; Lucas Liaudet; Bin Gao; Pál Pacher
Journal:  J Leukoc Biol       Date:  2007-07-25       Impact factor: 4.962

Review 4.  Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Authors:  Cecilia J Hillard
Journal:  Neuropsychopharmacology       Date:  2017-06-27       Impact factor: 7.853

Review 5.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 6.  Is lipid signaling through cannabinoid 2 receptors part of a protective system?

Authors:  P Pacher; R Mechoulam
Journal:  Prog Lipid Res       Date:  2011-02-02       Impact factor: 16.195

7.  Production of endocannabinoids by activated T cells and B cells modulates inflammation associated with delayed-type hypersensitivity.

Authors:  Jessica M Sido; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Eur J Immunol       Date:  2016-06       Impact factor: 5.532

Review 8.  Modulating the endocannabinoid system in human health and disease--successes and failures.

Authors:  Pál Pacher; George Kunos
Journal:  FEBS J       Date:  2013-04-22       Impact factor: 5.542

Review 9.  Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke.

Authors:  Somnath Mukhopadhyay; David A Tulis
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2007-10

Review 10.  Endocannabinoids and reactive nitrogen and oxygen species in neuropathologies.

Authors:  Allyn C Howlett; Somnath Mukhopadhyay; Derek C Norford
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-24       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.